{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:52Z","timestamp":1786984372562,"version":"build-2736575974"},"posted":{"date-parts":[[2026,5,14]]},"group-title":"In Review","reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,27]]},"abstract":"<title>Abstract<\/title>\n                <p>Stromal tumor infiltrating lymphocytes (sTILs), quantified via hematoxylin and eosin (H&amp;E) tumor slides, are associated with improved response to chemotherapy and better overall survival (OS) in triple-negative breast cancer (TNBC). Digitization of H&amp;E slides offers the opportunity for image-based computational approaches to enumerate sTILs. We describe QuTILs, a research-based TIL enumeration approach using a multilayer perceptron-based framework trained on open-source H&amp;E images using the QuPath software and executed on a standard computer. QuTILs was applied to H&amp;E images from two phase III TNBC clinical trials, CALGB 40502 and 40603 (total n\u2009=\u2009462 patients). In Cox proportional hazards models, QuTILs showed significant univariate association in CALGB 40502, with higher TIL% associated with reduced hazard (HR: 0.75, 95% CI: 0.63\u20130.91), which remained significant in multivariable models and validation CALGB 40603 TNBC clinical trial. In summary, QuTILs provides a computationally efficient, open-source workflow for sTIL identification from digital H&amp;E images for research application.<\/p>","DOI":"10.21203\/rs.3.rs-9535059\/v1","type":"posted-content","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:08:06Z","timestamp":1778760486000},"source":"Crossref","is-referenced-by-count":0,"title":["QuTILs: Open-Source Image-Based Infiltrating Immune Cell Detection for Research Application"],"prefix":"10.21203","author":[{"given":"Mark","family":"Vater","sequence":"first","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salgado","sequence":"additional","affiliation":[{"name":"Gasthuiszusters van Antwerpen Hospital (GZA) and Ziekenhuis Netwerk Antwerpen Hospital (ZNA)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Blige","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Strahan","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gatti-Mays","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Rugo","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Ballman","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Watson","sequence":"additional","affiliation":[{"name":"Washington University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wen","sequence":"additional","affiliation":[{"name":"University of Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Leon-Ferre","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Niazi","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Carey","sequence":"additional","affiliation":[{"name":"UNC Lineberger Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"AbdulJabbar","sequence":"additional","affiliation":[{"name":"Case45"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaibo","family":"Li","sequence":"additional","affiliation":[{"name":"Stefanie Spielman Comprehensive Breast Center, The Ohio State University Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G","family":"Stover","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies M","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350. Epub 20180423. doi: 10.1038\/s41591-018-0014-x. PubMed PMID: 29686425; PubMed Central PMCID: PMC5998822.","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.060","author":"Azizi E","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 2018;174(5):1293\u2009\u2013\u2009308 e36. Epub 20180628. doi: 10.1016\/j.cell.2018.05.060. PubMed PMID: 29961579; PubMed Central PMCID: PMC6348010."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses","volume":"11","author":"Labani-Motlagh A","year":"2020","unstructured":"Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Front Immunol. 2020;11:940. Epub 20200515. doi: 10.3389\/fimmu.2020.00940. PubMed PMID: 32499786; PubMed Central PMCID: PMC7243284.","journal-title":"Front Immunol"},{"issue":"2","key":"ref4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado R","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259\u201371. Epub 2014\/09\/13. doi: 10.1093\/annonc\/mdu450. PubMed PMID: 25214542.","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-020-0154-2","volume":"6","author":"Amgad M","year":"2020","unstructured":"Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, et al. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020;6:16. Epub 20200512. doi: 10.1038\/s41523-020-0154-2. PubMed PMID: 32411818; PubMed Central PMCID: PMC7217824.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/PAS.0000000000001409","article-title":"Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients","volume":"44","author":"Fuchs TL","year":"2020","unstructured":"Fuchs TL, Sioson L, Sheen A, Jafari-Nejad K, Renaud CJ, Andrici J, et al. Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients. Am J Surg Pathol. 2020;44(4):536\u201344. doi: 10.1097\/PAS.0000000000001409. PubMed PMID: 31743129.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert C","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350. Epub 20171207. doi: 10.1016\/S1470-2045(17)30904-X. PubMed PMID: 29233559.","journal-title":"Lancet Oncol"},{"issue":"27","key":"ref8","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams S","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959\u201366. doi: 10.1200\/JCO.2013.55.0491. PubMed PMID: 25071121; PubMed Central PMCID: PMC4162494.","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdy547","article-title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy","volume":"30","author":"Luen SJ","year":"2019","unstructured":"Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019;30(2):236\u201342. doi: 10.1093\/annonc\/mdy547. PubMed PMID: 30590484.","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03661-8","author":"Moraes FCA","year":"2024","unstructured":"de Moraes FCA, Souza MEC, Sano VKT, Moraes RA, Melo AC. Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. Clin Transl Oncol. 2024. Epub 20240818. doi: 10.1007\/s12094-024-03661-8. PubMed PMID: 39154313."},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: A report from","volume":"7","author":"Bairi K","year":"2021","unstructured":"El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150. Epub 20211201. doi: 10.1038\/s41523-021-00346-1. PubMed PMID: 34853355; PubMed Central PMCID: PMC8636568.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaoncol.2022.6288","article-title":"Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2\/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials","volume":"9","author":"Fernandez-Martinez A","year":"2023","unstructured":"Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, et al. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2\/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023;9(4):490\u20139. doi: 10.1001\/jamaoncol.2022.6288. PubMed PMID: 36602784; PubMed Central PMCID: PMC9857319.","journal-title":"JAMA Oncol"},{"issue":"4","key":"ref13","doi-asserted-by":"publisher","first-page":"e313-e27","DOI":"10.1093\/oncolo\/oyab063","article-title":"Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes","volume":"27","author":"Ni Y","year":"2022","unstructured":"Ni Y, Tsang JY, Shao Y, Poon IK, Tam F, Shea K-H, Tse GM. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes. The Oncologist. 2022;27(4):e313-e27. doi: 10.1093\/oncolo\/oyab063.","journal-title":"The Oncologist"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41523-018-0095-1","article-title":"Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer","volume":"4","author":"Altan M","year":"2018","unstructured":"Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, et al. Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. npj Breast Cancer. 2018;4(1):40. doi: 10.1038\/s41523-018-0095-1.","journal-title":"npj Breast Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/2153-3539.83746","article-title":"Review of the current state of whole slide imaging in pathology","volume":"2","author":"Pantanowitz L","year":"2011","unstructured":"Pantanowitz L, Valenstein PN, Evans AJ, Kaplan KJ, Pfeifer JD, Wilbur DC, et al. Review of the current state of whole slide imaging in pathology. J Pathol Inform. 2011;2:36. Epub 20110813. doi: 10.4103\/2153-3539.83746. PubMed PMID: 21886892; PubMed Central PMCID: PMC3162745.","journal-title":"J Pathol Inform"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/his.12993","article-title":"Digital pathology in clinical use: where are we now and what is holding us back?","volume":"70","author":"Griffin J","year":"2017","unstructured":"Griffin J, Treanor D. Digital pathology in clinical use: where are we now and what is holding us back? Histopathology. 2017;70(1):134\u201345. doi: 10.1111\/his.12993. PubMed PMID: 27960232.","journal-title":"Histopathology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/jpi.jpi_82_18","article-title":"Introduction to Digital Image Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology Association","volume":"10","author":"Aeffner F","year":"2019","unstructured":"Aeffner F, Zarella MD, Buchbinder N, Bui MM, Goodman MR, Hartman DJ, et al. Introduction to Digital Image Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology Association. J Pathol Inform. 2019;10:9. Epub 20190308. doi: 10.4103\/jpi.jpi_82_18. PubMed PMID: 30984469; PubMed Central PMCID: PMC6437786.","journal-title":"J Pathol Inform"},{"issue":"2","key":"ref18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jclinpath-2018-205328","article-title":"Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours","volume":"72","author":"Linder N","year":"2019","unstructured":"Linder N, Taylor JC, Colling R, Pell R, Alveyn E, Joseph J, et al. Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours. J Clin Pathol. 2019;72(2):157\u201364. Epub 20181205. doi: 10.1136\/jclinpath-2018-205328. PubMed PMID: 30518631.","journal-title":"J Clin Pathol"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ajpath.2020.03.012","article-title":"Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer","volume":"190","author":"Le H","year":"2020","unstructured":"Le H, Gupta R, Hou L, Abousamra S, Fassler D, Torre-Healy L, et al. Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer. Am J Pathol. 2020;190(7):1491\u2013504. Epub 20200408. doi: 10.1016\/j.ajpath.2020.03.012. PubMed PMID: 32277893; PubMed Central PMCID: PMC7369575.","journal-title":"Am J Pathol"},{"key":"ref20","author":"Abousamra S","year":"2021","unstructured":"Abousamra S, Gupta R, Hou L, Batiste R, Zhao T, Shankar A, et al. Deep Learning-Based Mapping of Tumor Infiltrating Lymphocytes in Whole Slide Images of 23 Types of Cancer. Front Oncol. 2021;11:806603.Epub 20220216. doi: 10.3389\/fonc.2021.806603. PubMed PMID: 35251953; PubMed Central PMCID: PMC8889499."},{"issue":"20","key":"ref21","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1158\/1078-0432.CCR-21-0325","article-title":"An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer","volume":"27","author":"Bai Y","year":"2021","unstructured":"Bai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, et al. An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. Clin Cancer Res. 2021;27(20):5557\u201365. Epub 20210604. doi: 10.1158\/1078-0432.CCR-21-0325. PubMed PMID: 34088723; PubMed Central PMCID: PMC8530841.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead P","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. Epub 20171204. doi: 10.1038\/s41598-017-17204-5. PubMed PMID: 29203879; PubMed Central PMCID: PMC5715110.","journal-title":"Sci Rep"},{"issue":"7","key":"ref23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41591-020-0900-x","article-title":"Geospatial immune variability illuminates differential evolution of lung adenocarcinoma","volume":"26","author":"AbdulJabbar K","year":"2020","unstructured":"AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med. 2020;26(7):1054\u201362. Epub 20200527. doi: 10.1038\/s41591-020-0900-x. PubMed PMID: 32461698; PubMed Central PMCID: PMC7610840.","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"103289","DOI":"10.1016\/j.media.2024.103289","article-title":"Foundation models for pathological slide analysis of H&E and IHC stains","volume":"97","author":"Hua S","year":"2024","unstructured":"Hua S, Yan F, Shen T, Ma L, Zhang X. PathoDuet: Foundation models for pathological slide analysis of H&E and IHC stains. Med Image Anal. 2024;97:103289. Epub 20240731. doi: 10.1016\/j.media.2024.103289. PubMed PMID: 39106763.","journal-title":"Med Image Anal"},{"issue":"8015","key":"ref25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41586-024-07441-w","article-title":"A whole-slide foundation model for digital pathology from real-world data","volume":"630","author":"Xu H","year":"2024","unstructured":"Xu H, Usuyama N, Bagga J, Zhang S, Rao R, Naumann T, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181\u20138. Epub 20240522. doi: 10.1038\/s41586-024-07441-w. PubMed PMID: 38778098; PubMed Central PMCID: PMC11153137.","journal-title":"Nature"},{"issue":"21","key":"ref26","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","article-title":"Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502\/NCCTG N063H (Alliance)","volume":"33","author":"Rugo HS","year":"2015","unstructured":"Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502\/NCCTG N063H (Alliance). J Clin Oncol. 2015;33(21):2361\u20139. Epub 20150608. doi: 10.1200\/JCO.2014.59.5298. PubMed PMID: 26056183; PubMed Central PMCID: PMC4500830.","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov WM","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13\u201321. Epub 20140804. doi: 10.1200\/JCO.2014.57.0572. PubMed PMID: 25092775; PubMed Central PMCID: PMC4268249.","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer","volume":"40","author":"Shepherd JH","year":"2022","unstructured":"Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022;40(12):1323\u201334. Epub 20220119. doi: 10.1200\/JCO.21.01506. PubMed PMID: 35044810; PubMed Central PMCID: PMC9015203.","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41523-024-00683-x","article-title":"Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502","volume":"10","author":"Stover DG","year":"2024","unstructured":"Stover DG, Salgado R, Savenkov O, Ballman K, Mayer EL, Magbanua MJM, et al. Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. NPJ Breast Cancer. 2024;10(1):75. Epub 20240821. doi: 10.1038\/s41523-024-00683-x. PubMed PMID: 39169033; PubMed Central PMCID: PMC11339397.","journal-title":"NPJ Breast Cancer"},{"key":"ref30","article-title":"A panoptic segmentation approach for tumor-infiltrating lymphocyte assessment: development of the MuTILs model and PanopTILs dataset","author":"Liu S","unstructured":"Liu S, Amgad M, Rathore MA, Salgado R, Cooper LA. A panoptic segmentation approach for tumor-infiltrating lymphocyte assessment: development of the MuTILs model and PanopTILs dataset. MedRxiv. 2022:2022.01. 08.22268814.","journal-title":"MedRxiv"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.086","author":"Saltz J","year":"2018","unstructured":"Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, et al. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep. 2018;23(1):181\u2009\u2013\u200993 e7. doi: 10.1016\/j.celrep.2018.03.086. PubMed PMID: 29617659; PubMed Central PMCID: PMC5943714."},{"issue":"18","key":"ref32","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1093\/bioinformatics\/btz083","article-title":"Structured crowdsourcing enables convolutional segmentation of histology images","volume":"35","author":"Amgad M","year":"2019","unstructured":"Amgad M, Elfandy H, Hussein H, Atteya LA, Elsebaie MA, Abo Elnasr LS, et al. Structured crowdsourcing enables convolutional segmentation of histology images. Bioinformatics. 2019;35(18):3461\u20137.","journal-title":"Bioinformatics"},{"issue":"2","key":"ref33","volume":"3","author":"Bradski G","year":"2000","unstructured":"Bradski G, Kaehler A. OpenCV. Dr Dobb\u2019s journal of software tools. 2000;3(2).","journal-title":"Dr Dobb\u2019s journal of software tools"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1038\/s41467-023-42635-2","article-title":"Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials","volume":"14","author":"Rediti M","year":"2023","unstructured":"Rediti M, Fernandez-Martinez A, Venet D, Rothe F, Hoadley KA, Parker JS, et al. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nat Commun. 2023;14(1):7053. Epub 20231103. doi: 10.1038\/s41467-023-42635-2. PubMed PMID: 37923752; PubMed Central PMCID: PMC10624889.","journal-title":"Nat Commun"},{"issue":"11","key":"ref35","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41416-023-02451-3","article-title":"Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence","volume":"129","author":"Makhlouf S","year":"2023","unstructured":"Makhlouf S, Wahab N, Toss M, Ibrahim A, Lashen AG, Atallah NM, et al. Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence. Br J Cancer. 2023;129(11):1747\u201358. Epub 20230930. doi: 10.1038\/s41416-023-02451-3. PubMed PMID: 37777578; PubMed Central PMCID: PMC10667537.","journal-title":"Br J Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"103492","DOI":"10.1016\/j.ebiom.2021.103492","article-title":"A Computational Tumor-Infiltrating Lymphocyte Assessment Method Comparable with Visual Reporting Guidelines for Triple-Negative Breast Cancer","volume":"70","author":"Sun P","year":"2021","unstructured":"Sun P, He J, Chao X, Chen K, Xu Y, Huang Q, et al. A Computational Tumor-Infiltrating Lymphocyte Assessment Method Comparable with Visual Reporting Guidelines for Triple-Negative Breast Cancer. EBioMedicine. 2021;70:103492. Epub 20210716. doi: 10.1016\/j.ebiom.2021.103492. PubMed PMID: 34280779; PubMed Central PMCID: PMC8318866.","journal-title":"EBioMedicine"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/CCI.19.00126","article-title":"Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data","volume":"4","author":"Lu Z","year":"2020","unstructured":"Lu Z, Xu S, Shao W, Wu Y, Zhang J, Han Z, et al. Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data. JCO Clin Cancer Inform. 2020;4:480\u201390. doi: 10.1200\/CCI.19.00126. PubMed PMID: 32453636; PubMed Central PMCID: PMC7265782.","journal-title":"JCO Clin Cancer Inform"},{"issue":"2","key":"ref38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/annonc\/mdv571","article-title":"Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer","volume":"27","author":"Pruneri G","year":"2016","unstructured":"Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann Oncol. 2016;27(2):249\u201356. Epub 20151123. doi: 10.1093\/annonc\/mdv571. PubMed PMID: 26598540.","journal-title":"Ann Oncol"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers","volume":"37","author":"Loi S","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37(7):559\u201369. Epub 20190116. doi: 10.1200\/JCO.18.01010. PubMed PMID: 30650045; PubMed Central PMCID: PMC7010425.","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial","volume":"1","author":"Salgado R","year":"2015","unstructured":"Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C, et al. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA oncology. 2015;1(4):448\u201354. Epub 2015\/07\/17. doi: 10.1001\/jamaoncol.2015.0830. PubMed PMID: 26181252.","journal-title":"JAMA oncology"},{"issue":"1","key":"ref41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert C","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105\u201313. Epub 2009\/11\/18. doi: 10.1200\/JCO.2009.23.7370. PubMed PMID: 19917869.","journal-title":"J Clin Oncol"},{"issue":"8","key":"ref42","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi S","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544\u201350. Epub 2014\/03\/13. doi: 10.1093\/annonc\/mdu112. PubMed PMID: 24608200.","journal-title":"Ann Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-025-01665-y","author":"Nagahashi M","year":"2025","unstructured":"Nagahashi M, Ishikawa E, Nagai T, Kanaoka H, Oshiro A, Togashi Y, et al. Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer. 2025. Epub 20250114. doi: 10.1007\/s12282-025-01665-y. PubMed PMID: 39808396."},{"issue":"5","key":"ref44","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/path.6165","article-title":"Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"260","author":"Page DB","year":"2023","unstructured":"Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, et al. Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. J Pathol. 2023;260(5):514\u201332. Epub 20230823. doi: 10.1002\/path.6165. PubMed PMID: 37608771; PubMed Central PMCID: PMC11288334.","journal-title":"J Pathol"},{"issue":"1","key":"ref45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41523-025-00728-9","article-title":"Spatial proximity of CD8(+) T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer","volume":"11","author":"Liang H","year":"2025","unstructured":"Liang H, Huang J, Li H, He W, Ao X, Xie Z, et al. Spatial proximity of CD8(+) T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer. NPJ Breast Cancer. 2025;11(1):13. Epub 20250210. doi: 10.1038\/s41523-025-00728-9. PubMed PMID: 39929822; PubMed Central PMCID: PMC11811209.","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"ref46","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8\u2009+\u2009T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali HR","year":"2014","unstructured":"Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8\u2009+\u2009T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536\u201343. Epub 2014\/06\/12. doi: 10.1093\/annonc\/mdu191. PubMed PMID: 24915873.","journal-title":"Ann Oncol"},{"issue":"7","key":"ref47","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00262-018-2150-z","article-title":"Quantifying tumor-infiltrating immune cells from transcriptomics data","volume":"67","author":"Finotello F","year":"2018","unstructured":"Finotello F, Trajanoski Z. Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol Immunother. 2018;67(7):1031\u201340. Epub 20180314. doi: 10.1007\/s00262-018-2150-z. PubMed PMID: 29541787; PubMed Central PMCID: PMC6006237.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"ref48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello F","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11(1):34. Epub 20190524. doi: 10.1186\/s13073-019-0638-6. PubMed PMID: 31126321; PubMed Central PMCID: PMC6534875.","journal-title":"Genome Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling Tumor Infiltrating Immune Cells with CIBERSORT","volume":"1711","author":"Chen B","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359. doi: 10.1007\/978-1-4939-7493-1_12. PubMed PMID: 29344893; PubMed Central PMCID: PMC5895181.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.14348\/molcells.2023.2178","article-title":"A Comprehensive Overview of RNA Deconvolution Methods and Their Application","volume":"46","author":"Im Y","year":"2023","unstructured":"Im Y, Kim Y. A Comprehensive Overview of RNA Deconvolution Methods and Their Application. Mol Cells. 2023;46(2):99\u2013105. doi: 10.14348\/molcells.2023.2178. PubMed PMID: 36859474; PubMed Central PMCID: PMC9982058.","journal-title":"Mol Cells"},{"issue":"1","key":"ref51","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41467-018-08023-x","article-title":"Bulk tissue cell type deconvolution with multi-subject single-cell expression reference","volume":"10","author":"Wang X","year":"2019","unstructured":"Wang X, Park J, Susztak K, Zhang NR, Li M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. Nat Commun. 2019;10(1):380. Epub 20190122. doi: 10.1038\/s41467-018-08023-x. PubMed PMID: 30670690; PubMed Central PMCID: PMC6342984.","journal-title":"Nat Commun"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7","author":"Li B","year":"2016","unstructured":"Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome biology. 2016;7(1), p.174. doi: 10.1186\/s13059-016-1028-7. PubMed PMID: 27549193; PubMed Central PMCID: PMC4993001."},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf388","author":"Cui H","year":"2025","unstructured":"Cui H, Zhao G, Lu Y, Zuo S, Duan D, Luo X, Zhao H, Li J, Zeng Z, Chen Q, Li T. TIMER3: an enhanced resource for tumor immune analysis. Nucleic Acids Research. 2025;53(W1), pp.W534-W541. doi: 10.1093\/nar\/gkaf388. PubMed PMID: 40337924; PubMed Central PMCID: PMC12230722."},{"issue":"1","key":"ref54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran D","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. Epub 20171115. doi: 10.1186\/s13059-017-1349-1. PubMed PMID: 29141660; PubMed Central PMCID: PMC5688663.","journal-title":"Genome Biol"},{"key":"ref55","author":"Racle J","year":"2017","unstructured":"Racle J, De Jonge K., Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife. 2017;6, p.e26476. doi: 10.7554\/eLife.26476. PubMed PMID: 29130882; PubMed Central PMCID: PMC5718706."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","author":"Yoshihara K","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, Trevi\u00f1o V, Shen H, Laird PW, Levine DA, Carter SL. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature communications. 2013;4(1), p.2612. doi: 10.1038\/ncomms3612. PubMed PMID: 24113773; PubMed Central PMCID: PMC3826632."},{"issue":"6","key":"ref57","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types","volume":"26","author":"Monaco G","year":"2019","unstructured":"Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carr\u00e9 C, Burdin N, Visan L, Ceccarelli M, Poidinger M, Zippelius A. RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell reports. 2019;26(6), pp.1627\u20131640. doi:10.1016\/j.celrep.2019.01.041. PubMed PMID: 30726743; PubMed Central PMCID: PMC6367568.","journal-title":"Cell reports"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902880","author":"Miao YR","year":"2020","unstructured":"Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, Guo AY. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Advanced science. 2020;7(7), p.1902880. doi: 10.1002\/advs.201902880. PubMed PMID: 32274301; PubMed Central PMCID: PMC7141005."},{"issue":"24","key":"ref59","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","article-title":"Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods","volume":"79","author":"Jim\u00e9nez-S\u00e1nchez A","year":"2019","unstructured":"Jim\u00e9nez-S\u00e1nchez A, Cast O, Miller ML. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Research. 2019;79(24), pp.6238\u20136246. doi: 10.1158\/0008-5472.CAN-18-3560. PubMed PMID: 31641003.","journal-title":"Cancer Research"},{"issue":"4","key":"ref60","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","article-title":"Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology","volume":"3","author":"Chu T","year":"2022","unstructured":"Chu T, Wang Z, Pe'er D, Danko CG. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat Cancer. 2022;3(4):505\u201317. Epub 20220425. doi: 10.1038\/s43018-022-00356-3. PubMed PMID: 35469013; PubMed Central PMCID: PMC9046084.","journal-title":"Nat Cancer"},{"issue":"1","key":"ref61","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1038\/s41598-021-83913-7","article-title":"CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer","volume":"11","author":"Craven KE","year":"2021","unstructured":"Craven KE, G\u00f6kmen-Polar Y, Badve SS. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci Rep. 2021;11(1):4691. Epub 20210225. doi: 10.1038\/s41598-021-83913-7. PubMed PMID: 33633150; PubMed Central PMCID: PMC7907367.","journal-title":"Sci Rep"},{"issue":"26","key":"ref62","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.7150\/thno.49451","article-title":"An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer","volume":"10","author":"Sui S","year":"2020","unstructured":"Sui S, An X, Xu C, Li Z, Hua Y, Huang G, et al. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics. 2020;10(26):11938\u201349. Epub 20201025. doi: 10.7150\/thno.49451. PubMed PMID: 33204321; PubMed Central PMCID: PMC7667685.","journal-title":"Theranostics"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9535059\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9535059\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:10:10Z","timestamp":1786983010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9535059\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":62,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9535059\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41523-026-01021-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,5,14]]},"subtype":"preprint"}}